comparison of Fingolimode and Betaferon(high dose) in M.S treatment

comparison of the effect of Fingolimode and Betaferon (high dose) in decreasing the symptoms and relapse rates of MS patients whose treatment with Betaferon (low dose) was failed.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015112025146N1

Enrollment

Registered

2016-02-18

Start date

2014-10-27

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M.S. Multiple Sclerosis

Interventions

Intervention 1: Fingolimode 0.5 mg /day will orally prescribe 18 months for a subgroup of patients who had treatment failure with Betaferon (low dose) during last year. Intervention 2: Betaferon high

Treatment - Drugs

Fingolimode 0.5 mg /day will orally prescribe 18 months for a subgroup of patients who had treatment failure with Betaferon (low dose) during last year.

Betaferon high dose s.c every 2 days will prescribe 18 months for the other subgroup of patients who had treatment failure during last year with Betaferon (low dose).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria:The most important one is MS patients who had treatment failure (relapsing rate more than one) under Betaferon ( low dose) ; patient acceptance; non immunosuppressive patient. Exclusion criteria: noncooperative patient; death

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Disability Status. Timepoint: befor intervention and 3.9.12.18 months after intervention. Method of measurement: Check list of E.D.S.S.;Relapse Numbers. Timepoint: 0,3,9,12,18 months after intervention. Method of measurement: History and observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPedram Moeini

Isfahan University of Medical Sciences

pmoeini@yahoo.com00

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026